Esperion Therapeutics | ESPR - Cash And Equivalent


Esperion Therapeutics reported $92.45M in Cash and Equivalent for its fiscal quarter ending in September of 2025.





Cash And Equivalent Change Date
AbbVie USD 5.23B 400M Dec/2025
Alnylam Pharmaceuticals USD 1.66B 167M Dec/2025
Alterity Therapeutics Limited AUD 15.77M 9.56M Jun/2023
Amarin USD 122.8M 25.08M Sep/2025
Amgen USD 9.13B 316M Dec/2025
Biogen USD 3.01B 854.3M Dec/2025
BioMarin Pharmaceutical USD 1.31B 61.57M Dec/2025
Cipla INR 7.96B 39.9M Sep/2025
CSL USD 2.16B 633M Jun/2025
Cytokinetics USD 122.52M 102.95M Dec/2025
Daiichi Sankyo JPY 542.16B 97.68B Sep/2025
Eli Lilly USD 7.27B 2.52B Dec/2025
Esperion Therapeutics USD 92.45M 6.39M Sep/2025
Geron USD 79.44M 553K Dec/2025
Grifols EUR 979.78M 334.84M Dec/2024
Halozyme Therapeutics USD 133.82M 285.84M Dec/2025
Heron Therapeutics USD 43.07M 26.55M Sep/2025
Ionis Pharmaceuticals USD 2.68B 437M Dec/2025
Merck USD 18.17B 10.16B Sep/2025
Minerva Neurosciences USD 12.29M 2.96M Sep/2025
Moderna USD 2.6B 1.46B Dec/2025
Nektar Therapeutics USD 41.03M 1.96M Sep/2025
Pfizer USD 1.34B 295M Sep/2025
PTC Therapeutics USD 984.65M 312.03M Dec/2025
Puma Biotechnology USD 53.52M 1.14M Sep/2025
Regeneron Pharmaceuticals USD 18.87B 16.36B Dec/2025
Sanofi EUR 7.66B 1.25B Dec/2025
Sarepta Therapeutics USD 801.28M 188.2M Dec/2025
United Therapeutics USD 1.56B 217M Dec/2025
Vanda Pharmaceuticals USD 84.85M 14.83M Dec/2025